Andrew Bellinger - Dec 16, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Scientific Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Stock symbol
VERV
Transactions as of
Dec 16, 2021
Transactions value $
$0
Form type
4
Date filed
12/17/2021, 03:41 PM
Previous filing
Jun 21, 2021
Next filing
Dec 27, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +55K $0.00 55K Dec 16, 2021 Common Stock 55K $34.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on December 16, 2021. 25% of the shares underlying the option will vest on December 16, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until December 16, 2025.